


Response to September 30, 2004 Office Action
Application No. 10/657,762
Attorney's Docket No. 02-166
Page 15

APPENDIX B

CLEAN COPY OF CLAIMS AS AMENDED HEREIN

1. A compound of the formula:



wherein:

R is hydrogen or lower alkyl;
R¹ is optionally substituted lower alkoxy or optionally substituted cycloalkyloxy;
R² is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or trialkylsilyl; and
R³ is hydroxymethyl or R⁴R⁵NC(O)-, where R⁴ and R⁵ are independently chosen from hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl.

2. The compound of claim 1, wherein R³ is hydroxymethyl.
3. The compound of claim 2, wherein R is hydrogen.
4. The compound of claim 3, wherein R¹ is methoxy, ethoxy, n-propoxy, isopropoxy, or cyclopropoxy.
5. The compound of claim 4, wherein R¹ is methoxy.
6. The compound of claim 5, wherein R² is phenyl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-[6-(methoxyamino)-2-(2-phenylethynyl)purin-9-yl]oxolane-3,4-diol.

Response to September 30, 2004 Office Action
Application No. 10/657,762
Attorney's Docket No. 02-166
Page 16

7. The compound of claim 5, wherein R^2 is 4-methylphenyl, namely (4S,2R,3R,5R)-5-hydroxymethyl-2-[6-(methoxyamino)-2-[(2(4-methylphenyl)ethynyl]purin-9-yl]oxolane-3,4-diol.
8. The compound of claim 5, wherein R^2 is 4-fluorophenyl, namely (4S,2R,3R,5R)-2-{2-[2-4-fluorophenyl]ethynyl}-6-(methoxyamino)purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol.
9. The compound of claim 5, wherein R^2 is 4-pentylphenyl, namely (4S,2R,3R,5R)-5-hydroxymethyl-2-{6-(methoxyamino)-2-[2-(4-pentylphenylethynyl)]purin-9-yl}oxolane-3,4-diol.
10. The compound of claim 5, wherein R^2 is 3-trifluoromethylphenyl, namely, (4S,2R,3R,5R)-5-(hydroxymethyl)-2-[6-(methoxyamino)-2-[(2(3-trifluoromethyl)phenyl]ethynyl]purin-9-yl]oxolane-3,4-diol.
11. The compound of claim 5, wherein R^2 is 4-methoxyphenyl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-[6-(methoxyamino)-2-[(2(4-methoxyphenyl)ethynyl]purin-9-yl]oxolane-3,4-diol.
12. The compound of claim 5, wherein R^2 is 4-cyanomethylphenyl, namely 6-{9-2-[4-(2-{9-[4S,2R,3R,5R]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methoxyamino)-purin-2-yl}ethynyl]phenyl}ethanenitrile.
14. The compound of claim 5, wherein R^2 is butyl, namely (4S,2R,3R,5R)-2-{2-[2-hex-1-ynyl-6-methoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol.
15. The compound of claim 5, wherein R^2 is 2-hydroxypropyl, namely (4S,2R,3R,5R)-2-[2-(4-hydroxypent-1-ynyl)-6-(methoxyamino) purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol.

Response to September 30, 2004 Office Action
Application No. 10/657,762
Attorney's Docket No. 02-166
Page 17

16. The compound of claim 5, wherein R^2 is 2-hydroxycyclohexyl, namely (4S,2R,3R,5R)-2-[-2-(2-hydroxycyclohexyl-1-ynyl)-6-(methoxyamino) purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol.
17. The compound of claim 5, wherein R^2 is 2-pyridyl, namely (4S,2R,3R,5R)-5-(hydroxymethyl)-2-[6-(methoxyamino)-2-[(2-(2-pyridyl)ethynyl) purin-9-yl]oxolane-3,4-diol.
18. The compound of claim 1, wherein R^3 is $R^4R^5NC(O)-$.
19. The compound of claim 18, wherein R is hydrogen.
20. The compound of claim 19, wherein R^1 is methoxy.
21. The compound of claim 20, wherein R^4 is hydrogen and R^5 is methyl or ethyl.
22. The compound of claim 21, wherein R^2 is optionally substituted phenyl or optionally substituted pyridyl.
23. The compound of claim 22, wherein R^2 is phenyl, 4-methylphenyl, 4-fluorophenyl, 3-trifluoromethylphenyl, 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl.
24. A method of treating a disease state by stimulating adenosine A_3 receptors, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of claim 1.
27. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of claim 1.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.